Data presented in partnership with T1D Exchange at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) support the efficacy and safety of needle-free glucagon nasal powder (GNP) for the treatment of severe hypoglycemia in youth with type 1 diabetes. Read the T1D Exchange press release here.